Kracov, Habtemariam Quoted in Bloomberg Law on FDA Reclassification of Certain Drugs to Devices
Life Sciences and Healthcare Regulatory partners Dan Kracov and Abeba Habtemariam were quoted in a recent article from Bloomberg Law, “Drug or Device? Manufacturers See Burden in FDA Reclassifying.” The article discusses the FDA’s potential reclassification of certain drugs as medical devices. Kracov, co-chair of the firm's Life Sciences and Healthcare Regulatory practice, comments on the industry reaction to the agency’s decision. Habtemariam notes a recent court ruling on drug and device definitions, reflecting on the whether the FDA will establish new classifications for those categories of agents.
» Read the full article (subscription required).